TERN Overview

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Wall Street analysts forecast TERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is54.22 USD with a low forecast of 35.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Terns Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

Terns Pharmaceuticals Inc. EPS for the last quarter amounts to -0.27 USD, decreased -3.57

Terns Pharmaceuticals Inc (TERN) has 59 emplpoyees as of March 12 2026.

Today TERN has the market capitalization of 5.09B USD.